Literature DB >> 22406169

Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody.

Bimmi Shrestha1, S Kyle Austin, Kimberly A Dowd, Abhishek N Prasad, Soonjeon Youn, Theodore C Pierson, Daved H Fremont, Gregory D Ebel, Michael S Diamond.   

Abstract

DENV1-E106 is a monoclonal antibody (MAb) with strong neutralizing activity against all five DENV-1 genotypes and therapeutic activity in mice. Here, we evaluated the potential for DENV-1 to escape neutralization by DENV1-E106. A single mutation in domain III of the envelope protein (T329A) emerged, which conferred resistance to DENV1-E106. However, the T329A variant virus had differing phenotypes in vitro and in vivo with attenuation in cell culture yet increased infectivity in Aedes aegypti mosquitoes. Mice infected with this T329A variant still were protected against lethal infection by DENV1-E106 even though much of the neutralizing activity was lost. This study reveals the complex dynamics of neutralization escape of an inhibitory MAb against DENV, and suggests that evaluation of therapeutic MAbs requires detailed investigation in relevant hosts. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22406169      PMCID: PMC3312934          DOI: 10.1016/j.virol.2012.02.010

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  38 in total

1.  Construction of a full length infectious clone for dengue-1 virus Western Pacific,74 strain.

Authors:  B Puri; S Polo; C G Hayes; B Falgout
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

2.  Differential susceptibility of Aedes aegypti to infection by the American and Southeast Asian genotypes of dengue type 2 virus.

Authors:  P M Armstrong; R Rico-Hesse
Journal:  Vector Borne Zoonotic Dis       Date:  2001       Impact factor: 2.133

3.  Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Authors:  Soila Sukupolvi-Petty; S Kyle Austin; Michael Engle; James D Brien; Kimberly A Dowd; Katherine L Williams; Syd Johnson; Rebeca Rico-Hesse; Eva Harris; Theodore C Pierson; Daved H Fremont; Michael S Diamond
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

4.  Quantifying the specific binding between West Nile virus envelope domain III protein and the cellular receptor alphaVbeta3 integrin.

Authors:  Jason Wei-Ming Lee; Justin Jang-Hann Chu; Mah-Lee Ng
Journal:  J Biol Chem       Date:  2005-11-07       Impact factor: 5.157

5.  Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.

Authors:  M H Tao; S L Morrison
Journal:  J Immunol       Date:  1989-10-15       Impact factor: 5.422

6.  The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.

Authors:  Bimmi Shrestha; James D Brien; Soila Sukupolvi-Petty; S Kyle Austin; Melissa A Edeling; Taekyung Kim; Katie M O'Brien; Christopher A Nelson; Syd Johnson; Daved H Fremont; Michael S Diamond
Journal:  PLoS Pathog       Date:  2010-04-01       Impact factor: 6.823

7.  Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

Authors:  Scott J Balsitis; Katherine L Williams; Ruben Lachica; Diana Flores; Jennifer L Kyle; Erin Mehlhop; Syd Johnson; Michael S Diamond; P Robert Beatty; Eva Harris
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

Review 8.  Pathogenesis of dengue: challenges to molecular biology.

Authors:  S B Halstead
Journal:  Science       Date:  1988-01-29       Impact factor: 47.728

Review 9.  Dengue: the risk to developed and developing countries.

Authors:  T P Monath
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

10.  Relative quantitation of virus population size in mixed genotype infections using sequencing chromatograms.

Authors:  Gerod S Hall; Damon P Little
Journal:  J Virol Methods       Date:  2007-07-19       Impact factor: 2.014

View more
  5 in total

1.  The Fc region of an antibody impacts the neutralization of West Nile viruses in different maturation states.

Authors:  Phong D Lee; Swati Mukherjee; Melissa A Edeling; Kimberly A Dowd; S Kyle Austin; Carolyn J Manhart; Michael S Diamond; Daved H Fremont; Theodore C Pierson
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

2.  Viral immune evasion in dengue: toward evidence-based revisions of clinical practice guidelines.

Authors:  Francesco Chiappelli; Silvana Maria Eloi Santos; Xenia Maria Caldeira Brant; Andre Bakhordarian; April D Thames; Carl A Maida; Angela M Du; Allison L Jan; Melissa Nahcivan; Mia T Nguyen; Nateli Sama
Journal:  Bioinformation       Date:  2014-12-31

3.  Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.

Authors:  Yadunanda Budigi; Eugenia Z Ong; Luke N Robinson; Li Ching Ong; Kirk J Rowley; Alexander Winnett; Hwee Cheng Tan; Sven Hobbie; Zachary Shriver; Gregory J Babcock; Sylvie Alonso; Eng Eong Ooi
Journal:  PLoS Negl Trop Dis       Date:  2018-02-09

4.  The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.

Authors:  Laura A VanBlargan; Swati Mukherjee; Kimberly A Dowd; Anna P Durbin; Stephen S Whitehead; Theodore C Pierson
Journal:  PLoS Pathog       Date:  2013-12-05       Impact factor: 6.823

5.  Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement.

Authors:  Melissa A Edeling; S Kyle Austin; Bimmi Shrestha; Kimberly A Dowd; Swati Mukherjee; Christopher A Nelson; Syd Johnson; Manu N Mabila; Elizabeth A Christian; Joseph Rucker; Theodore C Pierson; Michael S Diamond; Daved H Fremont
Journal:  PLoS Pathog       Date:  2014-04-17       Impact factor: 6.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.